

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 85113339.7

(51) Int. Cl.⁴: **A 61 K 31/54**

(22) Date of filing: 21.10.85

(30) Priority: 22.10.84 IT 2326384

(43) Date of publication of application:
30.04.86 Bulletin 86/18

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(71) Applicant: **CHIESI FARMACEUTICI S.p.A.**
Via Palermo, 26/A
I-43100 Parma(IT)

(72) Inventor: **Chiesi, Paolo**
Via Palermo 26/A
Parma(IT)

(72) Inventor: **Pavesi, Luciana**
Via Palermo 26/A
Parma(IT)

(74) Representative: **Bianchetti, Giuseppe**
Studio Consulenza Brevettuale Via Rossini, 8
I-20122 Milan(IT)

(54) **Aqueous pharmaceutical formulations of piroxicam monohydrate.**

(57) **Aqueous pharmaceutical compositions, containing as the active ingredient N-(2-pyridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide in the monohydrated form.**


The compositions of the invention are stable and do not undergo to crystal growth phenomena.

AQUEOUS PHARMACEUTICAL FORMULATIONS OF PIROXICAM MONOHYDRATE

The present invention relates to a process for the transformation of Piroxicam, N-(2-pyridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide into an hydrated form, suitable for oral, topic or parenteral administration.

More specifically, the invention relates to the use of Piroxicam in the monohydrated form in aqueous compositions for oral, topical or parenteral administration.

Piroxicam monohydrate is represented by the following formula:



The crystallographic characteristics of Piroxicam monohydrate are described in J. Border - Acta Cryst. C 40, 989, 1984.

Piroxicam is a compound effectively used in the treatment of arthrorreumatic affections, due to its remarkable analgesic and antiphlogistic activity.

Aqueous formulations containing Piroxicam, in form of a salt with both inorganic and organic bases, such as alkylamines and alkanolamines (EP 66459), amino acids (EP 66458) and combinations of polyhydroxylated alcohol with alkanolamines (EP 101178) are known; on the contrary,

- 2 -

various formulations containing Piroxicam in the free form are not known.

It is difficult to obtain aqueous compositions of Piroxicam, due to its particular chemico-physical characteristics. In fact, besides being insoluble in water when formulated in non-aqueous vehicles, such as excipients for creams, ointments, etc., containing even traces of water, it undergoes to the transformation into its hydrated form, which crystallizes in the medium, thus producing large yellow agglomerates.

It has now surprisingly been found, and it is an object of the present invention, that Piroxicam in the monohydrated form, prepared according to one of the methods hereinbelow described, does not form agglomerates, with a constant size of the particles suspended or dispersed in the aqueous compositions. Said characteristics advantageously allows to use the compound per se in pharmaceutical compositions for oral, topical or parenteral administration, not requiring the further use of organic or inorganic bases as salifying agents for the active ingredient. A further important advantage of the compositions according to the invention is provided by their remarkable stability for a long period of time.

The process for preparing Piroxicam monohydrate is very simple and unexpensive.

Generally Piroxicam, obtained as described in US Patent No. 3,591,584 by J.G. Lombardino, is dissolved in an aqueous solution, by addition of an inorganic base of an alkali or alkali earth metal, preferably potassium hydroxyde, or an organic base, generally water soluble

- 3 -

alkyl- or alkanol-amines, such as ethanolamine or aqueous ammonia.

At least one molar equivalent of an inorganic acid, such as hydrochloric acid, sulfuric acid, etc., or a water soluble organic acid, such as acetic or propionic acid, is added to the resulting solution.

The reaction is carried out at temperatures ranging from 20°C to 100°C, for 30 minutes to 3 hours.

After completion of the reaction, the yellow precipitate of Piroxicam monohydrate is easily recovered by means of conventional techniques, such as filtration, washing with water, drying in oven at temperatures between 20 and 60°C, until constant weight.

The obtained solid may be used as it is, or micronized into particles of 2-10 μ size.

The following examples further illustrate the present invention, without limiting the scope thereof.

EXAMPLE 1

To a 500 ml flask containing 30 ml of water, 18 ml (0.032 mole) of 10% KOH and 10.3 g (0.031 mole) of Piroxicam were added.

The resulting yellow solution was added, under stirring, with 11 ml (0.033 mole) of 3N HCl, thereafter with water to a final volume of about 300 ml.

25 . The reaction mixture was stirred at 30-35°C for about 2 hours, the obtained yellow precipitate was filtered, thoroughly washed with water, and dried in oven, under water pump vacuum, at 40°C for about 30 minutes, then at 60°C till constant weight.

30 10.8 Grams (100% yield) of Piroxicam monohydrate

- 4 -

($C_{15}H_{25}N_3O_5S.H_2O$) were obtained; m.p. 197-200°C.

Analysis

Potentiometric titre as the monohydrate 98.24%

Water K.F. 5.43%

5 Differential Scanning Calorimetry (D.S.C.).

A peak corresponding to the hydration water at about 125-130°C and the peak characteristic of Piroxicam at 200°C appear.

Starting temperature 50°C

10 Temperature gradient 10°C/min.

Final temperature 250°C.

The product was characterized also by spectrophotometric IR and NMR techniques, as well as elemental analysis.

15 EXAMPLE 2

To 600 ml of water, 25 ml of 30% ammonia was added, thereafter 10 g of Piroxicam was dissolved.

To the clear yellow solution, 20 ml of glacial acetic acid were added dropwise, under stirring, to adjust
20 the pH to 5-5.5.

Stirring was continued for about 30 minutes, then the reaction mixture was filtered.

The obtained residue was thoroughly washed with water and dried in oven at 45-50°C, to give a markedly
25 yellow powder.

The chemico-physical characteristic of the compound were the same as those of Example 1.

Piroxicam monohydrate, obtained according to the above described processes, showed an antiinflammatory
30 activity, by oral route in the rat, analogous to that of

- 5 -

anhydrous Piroxicam, in the standard test of carrageening oedema, according to the procedure of C.A. Winter et al. Proc. Soc. Exp. Biol. Med. 111, 544, 1967.

Piroxicam monohydrate may thus be used, similarly to anhydrous Piroxicam, in the treatment of arthrorheumatic affections.

The present invention further relates to the preparation of pharmaceutical compositions containing Piroxicam monohydrate as the active ingredient, in weight ratios of 0.2 to 5%, together with pharmaceutically acceptable excipients.

Said compositions may be administered by oral or parenteral route, in form of suspensions, or by topical route, in form of creams, ointments or gels.

For the preparation of pharmaceutical composition for oral administration in unitary dosage form, the active ingredient may be dispersed in water, by means of conventional vehicles and excipients, such as hydrophilic colloids deriving from cellulose, such as carboxymethylcellulose or microcrystalline cellulose; colloidal silicates, such as Al and Mg colloidal hydrate silicate; carbohydrates, such as saccharose; wetting agents, such as glycerol, sorbitol, polysorbate. The suspension may be stabilized by means of citrate or phosphate buffer, at pH ranging from 4.5 to 6.

In the formulations for parenteral administration, the active ingredient is micronized in particles of 2-10 μ size, preferably 2-5 μ , and formulated in aqueous suspensions containing appropriate vehicles and excipients, such as Al and Mg silicate; hydrophylic colloids, such as car-

boxymethylcellulose, methylcellulose; flocculation agents, such as aluminium chloride or monosodium citrate; and wetting agents, such as polysorbate. The suspension may be stabilized at pH about 4.5-6, using suitable buffers, 5 keeping isotonicity conditions by addition of sodium chloride.

The formulation is prepared in aseptic conditions, using apyrogenic and sterile starting materials.

In the formulations for topical administration, the 10 active principle may be dispersed in a cream containing 20-60% water, preferably 50%, and a fatty phase containing oils and waxes of natural or synthetic source; emulsifying agents such as glycerol esters or sorbitol with fat acids or polyoxyethylenate fat alcohols. To the aqueous phase, 15 polyols such as glycerol, sorbitol or propylene glycol may be added.

The compositions according to the present invention so prepared have been verified chemically and physically stable, even for a long time after the preparation.

20 Exemplificative formulations are reported hereinbelow.

Suspension formulation for oral administration

Piroxicam monohydrated (corresponding to 0.200 g of Piroxicam)	g	0.210
25 Polysorbates	g	0.100
Saccharose	g	24.000
Glycerol	g	4.000
Mycrocrystalline cellulose	g	1.246
Carboxymethylcellulose	g	0.154
30 Methyl p-hydroxybenzoate	g	0.100

- 7 -

Propyl p-hydroxybenzoate	g	0.010
Ethyl alcohol	g	0.700
Purified water and phosphate buffer at pH 4.5-5	q.s. to ml	100.

5 Suspension formulation for parenteral administration

Mycronized Piroxicam monohydrate	mg	21.0
Al e Mg hydrated colloidal silicate	mg	8.0
Carboxymethylcellulose	mg	24.0
Monobasic sodium citrate	mg	5.0
10 Sodium chloride	mg	14.3
Polysorbates	mg	2
Water	q.s. to ml	2.0.

The pH of the formulation is stabilized to values ranging from 4.5 to 6 by means of citrate or phosphate
15 buffer.

Cream formulation

Piroxicam monohydrate	g	1.050
Polyoxyethylen fatty alcohol	g	2.000
Propylen glycol	g	7.000
20 Cetostearilic alcohol	g	3.500
Fatty acids polyethylenglycolic ester	g	18.000
Water, preservatives and buffering agents to pH 4.5-6	q.s. to g	100.00.

CLAIMS for the Contracting States:

BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

- 5 1. Aqueous pharmaceutical compositions containing Piroxicam monohydrate as the active ingredient.
2. Pharmaceutical compositions of claim 1, wherein Piroxicam monohydrate has a particle size ranging from 2 to 10 μ .
- 10 3. Pharmaceutical compositions of claims 1 or 2, in form of suspension, for oral and parenteral administration, containing from 0.2 to 5% in weight of active ingredient per unitary dosage form.
4. Pharmaceutical compositions of claims 1 or 2, in
15 form of creams, ointments, lotions, unguents or gel, for topical administration, containing from 0.2 to 5% by weight of active principle per unitary dose.
5. A process for preparing Piroxicam monohydrate, stable in aqueous medium, characterized in that aqueous
20 solutions of Piroxicam salts with organic or inorganic base are treated at pH 5-6 with hydrosoluble organic or inorganic acids.
6. A process according to claim 5 characterized in that Piroxicam monohydrate is precipitated from Piroxicam
25 ammonium or potassium salt solutions by addition of hydrochloric or acetic acid.

- 9 -

CLAIMS for AT:

1. A process for preparing Piroxicam monohydrate, 5 stable in aqueous medium, characterized in that aqueous solutions of Piroxicam salts with organic or inorganic base are treated at pH 5-6 with hydrosoluble organic or inorganic acids.
2. A process according to claim 1 characterized in 10 that Piroxicam monohydrate is precipitated from Piroxicam ammonium or potassium salt solutions by addition of hydrochloric or acetic acid.
3. A process according to claim 1 or 2 wherein the obtained Piroxicam monohydrate has a particle size ranging 15 from 2 to 10 μ .

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.